Integral Health Asset Management LLC Acquires Shares of 150,000 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Integral Health Asset Management LLC purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 150,000 shares of the company's stock, valued at approximately $8,397,000. Integral Health Asset Management LLC owned approximately 0.24% of Rhythm Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in RYTM. Barclays PLC boosted its stake in shares of Rhythm Pharmaceuticals by 79.6% during the 3rd quarter. Barclays PLC now owns 106,397 shares of the company's stock worth $5,574,000 after acquiring an additional 47,166 shares in the last quarter. Franklin Resources Inc. boosted its stake in Rhythm Pharmaceuticals by 11.5% during the 3rd quarter. Franklin Resources Inc. now owns 259,416 shares of the company's stock valued at $13,033,000 after purchasing an additional 26,739 shares during the period. Raleigh Capital Management Inc. bought a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at approximately $28,000. KBC Group NV boosted its stake in Rhythm Pharmaceuticals by 78.2% during the 4th quarter. KBC Group NV now owns 2,251 shares of the company's stock valued at $126,000 after purchasing an additional 988 shares during the period. Finally, R Squared Ltd bought a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at approximately $44,000.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM traded down $0.25 during mid-day trading on Friday, reaching $59.93. The company had a trading volume of 687,672 shares, compared to its average volume of 553,622. Rhythm Pharmaceuticals, Inc. has a twelve month low of $35.17 and a twelve month high of $68.58. The company's 50-day moving average is $57.73 and its 200-day moving average is $57.37. The company has a market capitalization of $3.81 billion, a P/E ratio of -13.84 and a beta of 2.36.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The company had revenue of $37.72 million during the quarter, compared to analyst estimates of $40.43 million. During the same period in the previous year, the company posted ($2.35) earnings per share. The company's quarterly revenue was up 25.9% on a year-over-year basis. As a group, equities analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current fiscal year.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 20,760 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $60.14, for a total value of $1,248,506.40. Following the completion of the transaction, the insider now owns 19,209 shares in the company, valued at approximately $1,155,229.26. The trade was a 51.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Yann Mazabraud sold 75,000 shares of Rhythm Pharmaceuticals stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total value of $3,861,000.00. Following the completion of the transaction, the executive vice president now owns 40,370 shares of the company's stock, valued at approximately $2,078,247.60. The trade was a 65.01% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 143,639 shares of company stock valued at $8,023,381. Corporate insiders own 5.60% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on RYTM shares. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They set a "buy" rating and a $78.00 target price for the company. Morgan Stanley restated an "overweight" rating and set a $72.00 target price on shares of Rhythm Pharmaceuticals in a research note on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $80.00 target price (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research note on Tuesday, April 8th. Wells Fargo & Company increased their target price on Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an "overweight" rating in a research note on Monday, April 7th. Finally, Bank of America upgraded Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective for the company in a research report on Monday, April 7th. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, Rhythm Pharmaceuticals has a consensus rating of "Buy" and an average price target of $75.38.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.